Our purpose

We are bringing the power of precision radiopharmaceuticals into a new era.

Radiopharmaceuticals – a class of precision oncology medicines – are poised to transform the treatment of solid tumors. By hitching a radioisotope to a small molecule, these potent therapies can selectively deliver the proven power of radiation directly to tumors throughout the body.

We are applying our deep drug discovery and development expertise against novel cancer targets from a broad class of surface receptors to produce targeted small molecule radiopharmaceuticals. We seek to create effective new treatments for cancer patients that enable us to go far beyond what’s been done before – bringing us closer to the day we can say “cure.”

Innovative approach, immense possibilities

First-in-class targets for cancer

Targeting GPCRs, a vast and largely unexplored class for radiopharmaceuticals

Differentiated small molecule approach

Broadly enabling foundational platform based on decades of drug development experience

Modular flexible platform

Agnostic to alpha- or beta-emitting radioisotopes

Extensive pipeline

Moving multiple programs rapidly towards clinical development

Dual purpose enabling a targeted medicine approach

The versatile utility of radiopharmaceuticals is core to our development strategy.

Part of a treatment strategy known as theragnostics, radiopharmaceuticals can be used for both therapy and diagnosis.

Radiopharmaceuticals, when tethering a radionuclide suitable for imaging, create a map of cancerous tumors in the body that provides precise diagnostic information. From the imaging results, the patients who are most likely to respond are identified and treated with individualized regiments of the therapeutic version of the same radiopharmaceutical. This precision medicine approach seeks to make substantial improvements in clinical outcomes.


Broadly enabling technology to dramatically expand the application of radiopharmaceuticals.
We deliver targeted effects of radiation via optimal drug design.
small-molecule radiopharmaceutical targeting GPCR
We have built the only platform for the rapid discovery and development of novel small molecule radiopharmaceuticals that bind to GPCRs overexpressed on cancer cells.

Small molecules, tethered with powerful radioisotopes, are designed to exquisitely bind to receptors overexpressed in cancer and deliver powerful radiation to kill tumors, without affecting normal tissue.

Our unique approach marries a vast knowledge of GPCR biology with unrivaled proficiency in small molecule medicinal chemistry to develop potent and highly selective radiopharmaceuticals. We take a fit-for-purpose approach, pinpointing the precise target and selecting the ideal small molecule ligand paired with the optimal radioisotope to achieve a therapeutic effect.

Novel targets for solid tumors

GPCR family tree showing 132 peptide and protein GPCRs
GPCRs – expansive and largely unexplored target space for radiopharmaceuticals

Largest gene family in humans

132 known protein/receptor pairs

>65 with increased tumor expression

Given GPCR overexpression in many tumors, they can be targeted in a vast range of cancer indications, from common to rare tumors.

Clinical trials

Study R8760-101 is a multi-center Phase 1 clinical trial evaluating the safety and dosimetry of 68Ga-R8760, a first-in-class small molecule radioligand imaging agent being developed for patients diagnosed with adrenocortical carcinoma. 68Ga-R8760 was discovered by Radionetics Oncology for identifying melanocortin 2 receptor (MC2R)-expressing adrenocortical cancer lesions to select patients who may benefit from MC2R-directed radioconjugate therapy.

For additional information about the study, please see study NCT05999292

visit now


Frazier Life Sciences
5AM Ventures
Crinetics Pharmaceuticals
GordonMD Global investments


Scott Struthers, Ph.D.
Chairman; CEO
Dan Estes, Ph.D.
General Partner
Frazier Life Sciences
Andy J. Schwab
Managing Partner
5AM Ventures
Zachary Hornby
Boundless Bio
Eric Shiozaki, Ph.D.
Paul Grayson
Radionetics Oncology


join us

Join a fast-growing company with a deep foundation and vast opportunity, where every contribution matters.

Our location in the heart of San Diego’s thriving life sciences community means our team is made up of industry-leading experts in a range of disciplines and from a variety of backgrounds, united by a shared passion for turning science into meaningful discoveries for cancer patients.

Paul Grayson

Paul Grayson

Chief Executive Officer

Paul Grayson serves as Chief Executive Officer. Prior to joining Radionetics, he has been focusing on company origination, platform validation, IND enablement, and large and small molecule CMC through clinical proof of concept across a broad range of technologies and applications as both a CEO and a Venture Partner over the past 25 years. He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics. His previous experiences also include founding roles at BirdRock Bio (acquired by Skye Biosciences), Fate Therapeutics (NASDAQ: FATE), Senomyx (acquired by Firmenich), and Aurora Biosciences (acquired by Vertex Pharmaceuticals).

scroll to top